The Relative Strength (RS) Rating for ChemoCentryx entered a new percentile Thursday, with an increase from 78 to 81.
When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
ChemoCentryx is not currently showing a potential entry point, having fallen below key moving averages. See if the stock goes on to build a chart pattern that could launch a new move.
The company posted -27% EPS growth in the latest quarterly report. Revenue rose -47%. Keep an eye out for the company's next round of numbers on or around Aug. 9.
ChemoCentryx holds the No. 185 rank among its peers in the Medical-Biomed/Biotech industry group. Dynavax Technologies and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
